Kewaunee Scientific AI Stock Analysis
Want to see KEQU full AI Analyst Report?
Kewaunee Scientific (KEQU) AI Stock Analysis
Kewaunee Scientific
(NASDAQ:KEQU)
Improved profitability, balance-sheet strength, and reasonable valuation are the primary strengths. These are offset by slowing TTM growth, margin and cash-flow pressure, mixed technical momentum, and execution risk from the proposed acquisition.
Kewaunee Scientific Key Performance Indicators (KPIs)
Revenue by GeographyBreaks down revenue across different regions, revealing where Kewaunee Scientific is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Kewaunee’s growth is increasingly domestic-led: U.S. revenue stepped up materially in early 2025 and has remained near those elevated levels, while international revenue continues to fluctuate without reclaiming its 2023 peak. This improves near-term scale and visibility but also increases geographic concentration, making future performance more dependent on sustained U.S. laboratory, healthcare, and education demand. International operations remain a potential upside lever if the recent recovery develops into a durable trend.
The FlyKewaunee Scientific (KEQU) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $104.06M
- Dividend Yield
- ―
- Average Volume (3M)
- 4,065
- Price to Earnings (P/E)
- 12.3
- Beta (1Y)
- 1.25
- Revenue Growth
- 5.33%
- EPS Growth
- -33.32%
- Country
- US
- Employees
- 1,231
- Sector
- Consumer Cyclical
- Sector Strength
- 61
- Industry
- Furnishings, Fixtures & Appliances
Kewaunee Scientific Business Overview & Revenue Model
Company Description
Kewaunee Scientific Corporation, established in 1906 and based in Statesville, North Carolina, specializes in providing custom furniture and infrastructure systems for scientific, medical, and technical settings. The company manages its operations th...
How the Company Makes Money
Kewaunee primarily makes money by selling and installing laboratory infrastructure products and related project services. Its core revenue stream is the manufacture and sale of lab casework (e.g., benches, cabinets, and modular systems), fume hoods,...
Kewaunee Scientific Financial Statement Overview
Summary
The company has achieved a clear turnaround to consistent profitability, improved leverage, increased equity, and positive cash generation. Recent TTM revenue, margins, free cash flow, and cash-flow growth have weakened, limiting the score.
Income Statement
73PositiveBalance Sheet
82Very PositiveCash Flow
69Positive| Breakdown | TTM | Apr 2026 | Apr 2025 | Apr 2024 | Apr 2023 | Apr 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 277.21M | 282.00M | 240.47M | 203.75M | 219.49M | 168.87M |
| Gross Profit | 79.15M | 80.44M | 68.86M | 52.05M | 35.59M | 24.22M |
| EBITDA | 22.10M | 23.88M | 22.76M | 18.04M | 8.16M | 916.00K |
| Net Income | 8.23M | 9.62M | 11.40M | 18.75M | 1.36M | -6.00M |
Balance Sheet | ||||||
| Total Assets | 175.80M | 178.31M | 194.65M | 134.77M | 118.90M | 118.77M |
| Cash, Cash Equivalents and Short-Term Investments | 8.25M | 11.62M | 14.94M | 23.27M | 8.08M | 4.43M |
| Total Debt | 55.47M | 30.18M | 50.16M | 11.00M | 12.92M | 67.56M |
| Total Liabilities | 98.58M | 101.50M | 128.41M | 78.56M | 80.41M | 82.59M |
| Stockholders Equity | 75.00M | 74.72M | 64.46M | 54.76M | 37.41M | 35.69M |
Cash Flow | ||||||
| Free Cash Flow | 10.88M | 14.70M | 12.62M | 15.19M | -7.94M | -9.79M |
| Operating Cash Flow | 14.82M | 18.63M | 14.78M | 19.56M | -3.79M | -7.88M |
| Investing Cash Flow | -3.94M | -3.94M | -30.90M | -4.37M | -4.15M | -1.91M |
| Financing Cash Flow | -20.36M | -19.33M | 7.41M | -3.01M | 14.93M | 11.03M |
Kewaunee Scientific Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KEQU, the sentiment is Positive. The current price of 35.94 is above the 20-day moving average (MA) of 33.46, above the 50-day MA of 33.99, and below the 200-day MA of 36.59, indicating a neutral trend. The MACD of 0.17 indicates Negative momentum. The RSI at 64.38 is Neutral, neither overbought nor oversold. The STOCH value of 34.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for KEQU.
Kewaunee Scientific Risk Analysis
Kewaunee Scientific disclosed 28 risk factors in its most recent earnings report. Kewaunee Scientific reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksKewaunee Scientific Peers Comparison
Overall Rating
- KEQU71Outperform
FLXS70Outperform
HOFT59Neutral
BSET54Neutral
ETD54Neutral
VIRC54Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| KEQU | 71Outperform | $96.72M | 12.29 | 11.34% | ― | 5.33% | -33.32% |
| FLXS | 70Outperform | $311.73M | 11.25 | 19.83% | 1.20% | 3.40% | 48.89% |
| Sector * | 61Neutral | $18.38B | 12.79 | -2.54% | 3.03% | 1.52% | -15.83% |
| HOFT | 59Neutral | $153.22M | -8.64 | -10.59% | 3.16% | -28.13% | -38.44% |
| BSET | 54Neutral | $189.38M | 27.51 | 4.12% | 3.73% | 1.40% | -11.99% |
| ETD | 54Neutral | $462.75M | 14.36 | 6.90% | 27.16% | -7.44% | -33.97% |
| VIRC | 54Neutral | $101.05M | -41.08 | -2.32% | 1.57% | -18.97% | -118.61% |
* Consumer Cyclical Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| KEQU | Kewaunee Scientific | 35.94 | -4.48 | -11.08% | |
| BSET | Bassett Furniture Industries, Incorporated | 21.59 | 7.38 | 51.95% | |
| ETD | Ethan Allen Interiors | 17.71 | -0.83 | -4.50% | |
| FLXS | Flexsteel Industries, Inc. | 75.13 | 40.02 | 114.02% | |
| HOFT | Hooker Furniture | 14.56 | 4.57 | 45.77% | |
| VIRC | Virco Manufacturing | 6.36 | -0.47 | -6.87% |
Kewaunee Scientific Corporate Events
Kewaunee Scientific Agrees to Acquire Nycom Laboratory Dealer
PositiveOn November 2, 2026, Kewaunee agreed to acquire all outstanding equity interests of Nycom, described as the largest U.S. laboratory dealer, for a $55 million base price subject to EBITDA and customary adjustments. The agreement allocated $30 million...
Kewaunee Scientific Shareholders Endorse Board and Governance
PositiveOn August 26, 2026, Kewaunee Scientific Corporation held its Annual Meeting of Shareholders, where investors re-elected Class I directors Thomas D. Hull III, David S. Rhind, and John D. Russell to three-year terms, signaling continuity in the company...
Kewaunee Scientific Highlights Strong Fiscal 2026 Growth Strategy
PositiveKewaunee Scientific has posted an investor presentation and script for its August 26, 2026 virtual annual shareholder meeting, detailing multi-year growth, segment performance and the strategic integration of its Lab Products Group platform. The comp...
Kewaunee Scientific to Release Q1 FY2027 Results
NeutralOn August 25, 2026, Kewaunee Scientific Corporation announced it would release its first quarter fiscal year 2027 financial results on September 9, 2026, after the close of trading.The planned disclosure underscores the company’s ongoing communicatio...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 13, 2026